Disease and treatment characteristics of polycythemia vera patients in Belgium: Results from a scientific survey

No abstract is available for this paper.

• Publication year

  2018

• Venue

  European Journal of Haematology

• Publication date

  2018-04-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1111/ejh.13022PMID 29285836
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Ruxolitinib for the treatment of inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): a randomised, open-label, phase 3b study.

  2017cited by this paper
• Risk of thrombosis according to need of phlebotomies in patients with polycythemia vera treated with hydroxyurea

  2017cited by this paper
• After 10years of JAK2V617F: Disease biology and current management strategies in polycythaemia vera.

  2017cited by this paper
• Optimising the Use of Ruxolitinib in Inadequately Controlled Polycythaemia Vera

  2016cited by this paper
• Patterns of hydroxyurea use and clinical outcomes among patients with polycythemia vera in real-world clinical practice: a chart review

  2016cited by this paper
• The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia.

  2016cited by this paper
• Ruxolitinib versus best available therapy in patients with polycythemia vera: 80-week follow-up from the RESPONSE trial

  2016cited by this paper
• Current and future treatment options for polycythemia vera

  2015cited by this paper
• Ruxolitinib versus standard therapy for the treatment of polycythemia vera.

  2015cited by this paper
• CME Information: Polycythemia vera and essential thrombocythemia: 2015 update on diagnosis, risk-stratification, and management

  2015cited by this paper
• Epidemiology of myelofibrosis, essential thrombocythemia, and polycythemia vera in the European Union

  2014cited by this paper
• How I treat polycythemia vera.

  2014cited by this paper
• Epidemiology of myeloproliferative neoplasms in the United States

  2014cited by this paper
• Polycythemia vera disease burden: contributing factors, impact on quality of life, and emerging treatment options

  2014cited by this paper
• Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study

  2013cited by this paper
• A phase 2 study of ruxolitinib, an oral JAK1 and JAK2 inhibitor, in patients with advanced polycythemia vera who are refractory or intolerant to hydroxyurea

  2013cited by this paper
• Front-line therapy in polycythemia vera and essential thrombocythemia.

  2012cited by this paper
• Assessment and prognostic value of the European LeukemiaNet criteria for clinicohematologic response, resistance, and intolerance to hydroxyurea in polycythemia vera.

  2012cited by this paper
• How I treat polycythemia vera.

  2012cited by this paper
• The Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF): international prospective validation and reliability trial in 402 patients.

  2011cited by this paper
• Polycythemia vera

  2010cited by this paper
• A unified definition of clinical resistance and intolerance to hydroxycarbamide in polycythaemia vera and primary myelofibrosis: results of a European LeukemiaNet (ELN) consensus process

  2010cited by this paper
• Incidence of hematologic malignancies in Europe by morphologic subtype: results of the HAEMACARE project.

  2010cited by this paper
• Classification and diagnosis of myeloproliferative neoplasms: The 2008 World Health Organization criteria and point-of-care diagnostic algorithms

  2008cited by this paper
• Thrombosis in myeloproliferative disorders: prevalence, prognostic factors, and the role of leukocytes and JAK2V617F.

  2007cited by this paper
• The burden of fatigue and quality of life in myeloproliferative disorders (MPDs)

  2007cited by this paper
• Leukemic transformation in myelofibrosis with myeloid metaplasia: a single-institution experience with 91 cases.

  2005cited by this paper
• Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia.

  2004cited by this paper

• Polycythemia Vera and Essential Thrombocythemia: A Nationwide Population-Based Study on Treatment Patterns, Vascular Complications and Survival.

  2026cites this paper
• Prevalence, incidence, and thromboembolic events in polycythemia vera: a study based on longitudinal German health claims data

  2025cites this paper
• Real-world patient characteristics and treatment patterns of polycythemia vera in Taiwan between 2016 and 2017: a nationwide cross-sectional study

  2023cites this paper
• Real-World Clinical Characterisation of Polycythaemia Vera Patients from a Prospective Registry in Portugal: Is Resistance to Hydroxyurea a Reality?

  2023cites this paper
• Ruxolitinib versus best available therapy in inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): 5-year follow up of a randomised, phase 3b study.

  2022cites this paper
• Patterns of Hydroxyurea Prescription and Use in Routine Clinical Management of Polycythemia Vera: A Multicenter Chart Review Study

  2020cites this paper
• Treatment strategies for polycythemia vera: Observations in a Dutch “real‐world” cohort study

  2019cites this paper